In experimental IgA nephropathy, treatment with a neutralizing MIF antibody can inhibit IgAN by blocking TGF-β1 expression [66], suggesting a role of MIF in the pathogenesis of IgAN. The gene discussed is TGFB1; the disease is IgA glomerulonephritis.